CD38 | CD molecules | IUPHAR Guide to IMMUNOPHARMACOLOGY

Top ▲

CD38

Target id: 2766

Nomenclature: CD38

Family: CD molecules

Annotation status:  image of a grey circle Awaiting annotation/under development. Please contact us if you can help with annotation.  » Email us

   GtoImmuPdb view: ON :     CD38 has curated data in GtoImmuPdb

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 300 4p15.32 CD38 CD38 molecule 6
Mouse - 304 5 B3 Cd38 CD38 antigen
Rat 1 303 14q21 Cd38 CD38 molecule
Previous and Unofficial Names
ADP-ribosyl cyclase 1
Database Links
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
RefSeq Nucleotide
RefSeq Protein
SynPHARM
UniProtKB
Wikipedia
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Description:  Crystal structure of CD38 with a novel CD38-targeting antibody SAR650984 (=isatuximab).
PDB Id:  4CMH
Ligand:  isatuximab
Resolution:  1.53Å
Species:  Human
References:  3

Download all structure-activity data for this target as a CSV file

Antibodies
Key to terms and symbols Click column headers to sort
Antibody Sp. Action Affinity Units Reference
isatuximab Hs Binding 8.5 – 10.0 pKd 7
pKd 8.5 – 10.0 (Kd 3x10-9 – 1x10-10 M) [7]
daratumumab Hs Antagonist 8.2 pKd 2
pKd 8.2 (Kd 6.06x10-9 M) [2]

References

Show »

1. Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KC. (2018) Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia, 32 (2): 252-262. [PMID:29257139]

2. De Weers M, Graus Y, Oprins J, Parren P, Van De Winkel J, Van Vugt M. (2010) Antibodies Against Cd38 For Treatment Of Multiple Myeloma. Patent number: US7829673. Assignee: Genmab A/S. Priority date: 23/03/2005. Publication date: 09/11/2010.

3. Deckert J, Wetzel MC, Bartle LM, Skaletskaya A, Goldmacher VS, Vallée F, Zhou-Liu Q, Ferrari P, Pouzieux S, Lahoute C et al.. (2014) SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin. Cancer Res., 20 (17): 4574-83. [PMID:24987056]

4. Ellis JH, Barber KA, Tutt A, Hale C, Lewis AP, Glennie MJ, Stevenson GT, Crowe JS. (1995) Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. J. Immunol., 155 (2): 925-37. [PMID:7608568]

5. Hamblin TJ. (2003) CD38: what is it there for?. Blood, 102: 1939-1940.

6. Jackson DG, Bell JI. (1990) Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation. J. Immunol., 144 (7): 2811-5. [PMID:2319135]

7. Park PU, Bartle L, Skaletskaya A, Golmakher V, Tavares D, Deckert J, Milol V, Blanc V. (2011) Novel anti-cd38 antibodies for the treatment of cancer. Patent number: US20110262454 A1. Assignee: Sanofi-Aventis. Priority date: 20/08/2015. Publication date: 27/10/2011.

8. Roepcke S, Plock N, Yuan J, Fedyk ER, Lahu G, Zhao L, Smithson G. (2018) Pharmacokinetics and pharmacodynamics of the cytolytic anti-CD38 human monoclonal antibody TAK-079 in monkey - model assisted preparation for the first in human trial. Pharmacol Res Perspect, 6 (3): e00402. [PMID:29864242]

How to cite this page

CD molecules: CD38. Last modified on 31/07/2018. Accessed on 16/01/2019. IUPHAR/BPS Guide to PHARMACOLOGY, http://guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=2766.